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yet do not believe it truly exists. What manner of discov-
ery Arg441His truly is, only time will tell. I, for one, would
gamble on treasures beyond the beachhead. But it may
be a treasure of small gems, one that must be
appreciated in the context of other jewels, mined else-
where and assembled patiently over time, to be
a crowning achievement.
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Zhang et al. reported a naturally occurring Arg441His
missense variant of the human tryptophan hydroxy-
lase-2 (TPH2) gene. The His441 allele was reported tobe more abundant in a cohort of 87 depressed patients
compared to 219 controls (Zhang et al., 2005). The fre-
quency of His441 was higher in the depressed patients
(0.06), among whom there were two His/His homozy-
gotes and seven heterozygotes. His441 was also ob-
served among the 219 controls (allele frequency
0.009), among whom one His/His homozygote and two
Arg/His heterozygotes were detected. This reported as-
sociation with depression is of note in the context of the
effect of this substitution in reducing serotonin synthe-
sis by approximately 80% in a heterologous expression
assay in a rat cell line (Zhang et al., 2005) and through the
observation of the role of TPH2 variants as genetic pre-
dictors of depression (Zill et al., 2004) and response to
antidepressants (Peters et al., 2004).
The authors of this letter represent three independent
groups of investigators who have resequenced the rele-
vant region of TPH2 in some 779 unrelated individuals
(Table 1), including 403 with major depression (ages
19–74, n = 21 > 60 years). In addition, another 1740 indi-
viduals with major depression (from the STAR*D study,
ages 18–75, n = 121 > 60 years) were genotyped (Table
1). The sequenced and genotyped individuals represent
five ethnic populations. Psychiatric assessment was
accomplished using semistructured psychiatric inter-
views: NIAAA, SCID or SADS-L; NIMH and UCSF,
SCID-I/P. Major depression was diagnosed by DSM-
III-R or DSM-IV criteria, and a DSM-IV checklist was
used for the STAR*D samples. Additional descriptions
of individual data sets have been reported (Nielsen
et al., 1998; Robin et al., 1997; Roy, 2003; Peters
et al., 2004; Rush et al., 2004). All data were collected
following informed consent and under human research
protocols approved by IRBs of the respective institu-
tions. For direct sequencing, genomic DNA was ampli-
fied by PCR with primers encompassing the Arg441His
variant, sequenced using the BigDye Terminator V3.1
(Applied Biosystems Inc., Foster City, CA) and analyzed
on ABI 3100 or 3730 sequencers. For genotyping, as-
says were performed using 50-nuclease assay (TaqMan,
ID # PMT06-55) and analyzed on an LJL plate reader
(Molecular Devices, Sunnyvale, CA). 20% of theTable 1. Individuals Sequenced or Genotyped for TPH2 Arg441His
Direct Sequencing
Genotyping
NIAAA UCSF NIMH Total NIMH
Major depression 295 108 403 1740
Caucasian 124 83 207 1411
African American 63 8 71 213
American Indian 101 0 101 0
Hispanic 0 11 11 0
Asian-American 2 6 8 0
Others 5 0 5 116
Control 152 200 352
Caucasian 87 100 187
African American 63 100 163
American Indian 2 0 2
Bipolar 24 24
Caucasian 24 24
African American
American Indian
Total 447 308 24 779 1740
Grand total 2519
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703Table 2. Probabilities of Not Detecting the TPH2 Arg441His Variant in Resequenced Samples at Various His441 Allele Frequencies
Major Depression (403)
Frequency 0.06 0.03 0.01 0.005 0.003
Probability 10222 10211 0.0003 0.017 0.089
Overall (779)
Frequency 0.01 0.005 0.003 0.002 0.001
Probability 1027 0.0004 0.009 0.044 0.21samples were re-genotyped on an ABI 7900, and no dis-
crepancies were observed. An Arg/His heterozygous
DNA kindly provided by M. Caron (Duke University) was
used as a positive control for both sequencing and ge-
notyping.
We observed the His441 allele in neither depressed
patients nor controls. This represents a total of 1558
chromosomes that were Arg441 by direct sequencing
and 3480 that were Arg441 by genotyping. Direct se-
quencing and genotyping are both imperfect for detect-
ing heterozygous sequence variation. However, DNA
sequencing was performed on genomic DNA amplified
using multiple different sets of primers. Sequencing was
bidirectional, and multiple sequencing primers were also
used. Uncommon, previously unknown TPH2 missense
variants were detectable by sequencing: Pro206Ser
(Z.Z.), Arg55Cys (Z.Z.), and Ser41Tyr (S.P.H.). Further-
more, the sequence chromatograms for exon 11, where
Arg441His resides,wereunambiguous.Finally, theHis441
allele was readily detectable by both sequencing and
genotyping in positive control heterozygous DNA.
Interestingly, a recent resequencing effort in a small
number of individuals (n = 48) also failed to detect
His441 (Breidenthal et al., 2004).
Based on our sequencing data alone and using the bi-
nomial distribution, we rule out that His441 is as com-
mon as 0.06 in patients with major depression (Table
2). Also, based on a threshold probability of p > 0.01,
the maximum allele frequency in patients with major de-
pression is 0.005. If the genotyping data are included,
the maximum allele frequency in patients with major de-
pression is 0.001.
It is notable that Zhang et al. observed four His441/
His441 homozygotes among 366 individuals, even
though our data predict that the frequency of such ho-
mozygotes should be less than one per million. In con-
trast, we saw neither heterozygotes nor homozygotes
among 2519 people. It is possible that His441 is a rare
TPH2 allele that may or may not be linked to major de-
pression or other behavior. If it is linked to behavior, we
suspect that important clues to explain the association
may be found in some of the demographic or phenotypic
characteristics of the Zhang et al. sample, which in con-
trast to the populations we studied was geriatric—with a
minimum age of 60 years. If that is the case, the His441
allele could be correlated with late-onset depression.
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